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Aims: Under- and, especially, overdosing of replacement therapy in haemophilia A
patients may be prevented by application of other morphometric variables than body
weight (BW) to dose factor VIII (FVIII) concentrates. Therefore, we aimed to investi-
gate which morphometric variables best describe interindividual variability (IIV) of
FVIII concentrate pharmacokinetic (PK) parameters.
Methods: PK profiling was performed by measuring 3 FVIII levels after a standardized
dose of 50 IU kg−1 FVIII concentrate. A population PK model was constructed, in which
IIV for clearance (CL) and central volume of distribution (V1) was quantified. Relationships
between CL, V1 and 5 morphometric variables (BW, ideal BW [IBW], lean BW, adjusted
BW, and body mass index [BMI]) were evaluated in normal weight (BMI < 25 kg m−2),
overweight (BMI 25–30 kg m−2) and obese haemophilia A patients (BMI > 30 kg m−2).
Results: In total, 57 haemophilia A patients (FVIII≤0.05 IU mL−1) were included with
median BW of 83 kg (range: 53–133) and median age of 48 years (range: 18–77).
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IBW best explained observed variability between patients, as IIV for CL and V1 was
reduced from 45.1 to 37.6 and 26.% to 14.1%, respectively. CL, V1 and half-life were
similar for all BMI categories. The national recommended dosing schedule did not
result in adequate trough levels, both in case of dosing based on BW and IBW. How-
ever, dosing based on IBW prevented unnecessary high FVIII peaks.
Conclusion: IBW is the most suitable morphometric variable to explain
interindividual FVIII PK variability and is more appropriate to dose overweight and
obese patients.
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haemostasis, modelling and simulation, obesity, pharmacokinetics
1 | INTRODUCTION
Haemophilia A is an X-linked inherited bleeding disorder caused by a
deficiency in coagulation factor VIII (FVIII).1 To prevent and treat
bleeding in muscles and joints, haemophilia A patients are infused
either prophylactically or on demand with intravenous replacement
therapy consisting of recombinant or plasma-derived FVIII concen-
trates.2,3 Current FVIII concentrate dosing schedules are based on
body weight (BW). It is, however, well-known that a large inter-
individual variability (IIV) exists in observed FVIII levels after FVIII con-
centrate infusion, which results in both under- and overdosing when
specific FVIII ranges are targeted.4,5
Dosing based on pharmacokinetics (PK) is able to reduce under-and
overdosing. However, when applying this method, an individual's char-
acteristics should be comparable to those individuals which have con-
tributed data to the population PK model. In haemophilia A, this is
especially important for age and BW, as these characteristics have been
shown to be closely associated with FVIII PK.5 Recently, a meta-analysis
in haemophilia patients demonstrated that the prevalence of over-
weight and obesity is steadily increasing with a pooled prevalence that
has risen from 17% (95% CI: 15.0–19.3%) to 31% (95% CI: 26.8–36.2%)
in the last decade.6 This underlines the urgency to include representa-
tive numbers of overweight and obese patients in population PK dosing
models for factor concentrates in haemophilia treatment.
More specifically, several authors report that obese patients
defined as individuals with a body mass index (BMI) >30 kg m−2 have
a higher in vivo recovery (IVR) of intravenously administered factor
concentrates than patients with a normal BMI, defined as a BMI of
20–25 kg m−2.7,8 This is explained by the fact that obese patients
receive higher weight-based doses that distribute over similar vol-
umes of distribution to those measured in normal weight individuals,
as the intravascular compartment does not increase with weight gain.
This is, however, especially relevant for FVIII peak levels, as FVIII
trough levels and steady state FVIII levels are more dependent on
FVIII clearance.9 As parameters from a population PK model are gen-
erally scaled using BW of the patient,4,5,10 other morphometric vari-
ables that also take body composition into account may have a higher
predictive performance when describing FVIII PK parameters in
overweight and obese haemophilia A patients.11,12 Various population
models describe PK variability observed after FVIII concentrate dosing
in haemophilia A patients, incorporating different morphometric vari-
ables such as BW, lean body mass (LBM) or ideal BW (IBW).4,5,13
However, no study has yet investigated how different morphometric
variables correlate with FVIII PK parameters using population PK
modelling with real-world data from haemophilia A patients treated
with various FVIII concentrates. In addition, risk analyses for such an
approach have not yet been reported.
Therefore, this study explores the extent to which morphometric
variables other than BW explain IIV of FVIII PK parameters in normal,
overweight and obese haemophilia A patients. Our study is the first to
apply population PK analysis using real-world data from patients of
whom a representative number is overweight or obese. In addition,
What is already known about this subject
• Dosing of factor VIII (FVIII) concentrates in haemophilia A
patients based on body weight leads to both under-and
overdosing.
• Population pharmacokinetics (PK) enables investigation
of the relationship between various morphometric vari-
ables and FVIII concentrate PK.
What this study adds
• Ideal body weight (IBW) best explains PK variability
between patients with varying body mass index.
• Application of IBW avoids overdosing of factor VIIII con-
centrate in overweight and obese patients.
• The national recommended dosing schedule did not
result in adequate trough levels, both in case of dosing
based on body weight and IBW. However, dosing based
on IBW prevented unnecessary high FVIII peaks.
2 van MOORT ET AL.
the risks of this real-world population PK model are also simulated to




In this cross-sectional study, severe and moderate haemophilia A
patients were included with endogenous baseline FVIII activity
levels ≤0.05 IU mL−1, aged ≥18 years, and without inhibitory
FVIII antibodies (Bethesda Units [BU] <0.2 IU). Patients were enrolled
from 6 Academic Hemophilia Treatment Centers in the Netherlands
(Erasmus University Medical Center Rotterdam, University Medical
Center Groningen, University Medical Center Utrecht, Radboud
University Medical Center Nijmegen/Maxima Medical Center,
Veldhoven, Leiden University Medical Center/Haga Hospital, The
Hague, Amsterdam University Medical Centers). This study was
approved by the Medical Ethics Committee of the Erasmus University
Medical Center and all patients gave written informed consent before
enrollment according to the declaration of Helsinki. Although data
mostly originates from patients enrolled in the perioperative
OPTI-CLOT trial14 (n = 48) and consists of preoperative individual PK
profiling data, some patients (n = 9) were included from a separate
study investigating PK tools for FVIII dosing.15 This study was not
subject to the Medical Research Involving Human Subjects Act
(WMO) and was approved by the Medical Ethics Committee of the
Erasmus University Medical Center.
2.2 | Blood sampling and analyses
A single intravenous dose of 50 IU kg−1 FVIII concentrate was admin-
istered to each patient. Patients received the following recombinant
FVIII concentrates (Kogenate FS: Bayer, Berkeley, Ca, USA; Advate:
Baxter Bioscience, Thousand Oaks, CA, USA; Refacto AF: Pfizer,
New York, NY USA; NovoEight: Novo Nordisk, Bagsværd, Denmark)
or plasma-derived FVIII concentrates (Aafact: Blood Transfusion coun-
cil of the Netherlands Red Cross, Amsterdam, the Netherlands). In
general, 3 FVIII level measurements were obtained at 4, 24 and
48 hours after FVIII bolus administration. In a minority of patients, a
preinfusion FVIII level was also measured. The need for a washout
period and baseline measurement was avoided by collecting time of
dosing and doses of 3 previous FVIII concentrate infusions. FVIII
plasma levels were measured locally in each treatment centre, using a
1-stage clotting assay.
2.3 | Morphometric variables
For each patient, the following patient characteristics were collected:
endogenous baseline FVIII level (IU mL–1); inhibitor status; age (mo);
BW (kg) and height (cm). LBM was determined using a bioelectrical
impedance analyser (Maltron BF-906, Maltron International, Rayleigh,
UK). Using the BW and height of the patient, the following morpho-
metric variables were calculated: BMI (kg m−2)16; IBW (kg)17; adjusted
BW (kg)17; and calculated LBM (kg).18 The equations used to calculate
morphometric variables are presented in Supplementary Table S1.
Patients were categorized into 3 BMI categories: normal weight
patients (BMI < 25 kg m−2), overweight patients (25 kg m−2 ≤
BMI ≤ 30 kg m−2), and obese patients (BMI > 30 kg m−2).
2.4 | PK modelling
A structural population PK model was constructed describing IIV of
PK parameters. Models were compared using the objective function
value (OFV). If the difference of the OFV between 2 models was
larger than 3.84 it was considered to be statistically significant with a
P < .05. Subsequently, the extent to which the various morphometric
variables explained this variability was evaluated (applied equations
are described in Supplementary S1)
The structural PK model was developed using nonlinear mixed-
effects modelling software NONMEM v7.4 (ICON Development
Solutions, Ellicott City, MD, USA) with the FVIII level data of all
patients simultaneously. The endogenous baseline FVIII activity
level for each patient, especially important in the moderate
haemophilia patients (FVIII 0.01–0.05 IU mL–1), at time of individ-
ual PK profiling was calculated by subtraction from predicted FVIII
levels. Moreover, residual FVIII levels due to previous prophylacti-
cally administered FVIII concentrate doses were also taken into
account.
The following PK parameters were estimated: clearance (CL),
intercompartmental clearance (Q), and volume of distribution of the
central (V1) and peripheral (V2) compartment. R software v3.4.1
(R Core Team; 2017) and Xpose v4.5.3 were used for data exploration
and model diagnostics.19
2.5 | Evaluation of the morphometric variables
After establishing the structural population PK model, the ability of
the morphometric variables to explain IIV of the obtained popula-
tion PK parameters was evaluated. The difference between 2 values
for OFV (dOFV) from 2 different models can be described by χ2
distribution in the case of nested models and, hence, a statistical
significance can be calculated in terms of a P-value. However, the
OFV does not consider the difference in number of parameters
between 2 evaluated models. The Akaike information criterion
(AIC) is based on the OFV and adds a penalty for the number of
parameters from the corresponding model. For calculating AIC, the
evaluated models do not necessarily have to be nested. As the
model with the least number of parameters and the highest ability
to describe measured FVIII levels is most favourable, AIC was used
instead of OFV in this study evaluation. Besides the predictive
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ability of the model, reduction in IIV of CL and V1 was considered
for model selection as well.
Allometric scaling was used to describe the correlation between







in which θTV is the typical value for the population PK parameter
(i.e. the median value), θPop is the estimated population value for the
population PK parameter, MVi and MVmed are the individual value and
median for the morphometric variable, respectively, and EXPallo is the
allometric exponent.
Allometric scaling was evaluated in 2 ways. Firstly, relationships
between morphometric variables and PK parameters were evaluated
with EXPallo fixed to the values of 0.75 and 1 for the clearance param-
eters (CL and Q) and for the volume of distribution parameters
(V1 and V2), respectively.20 Secondly, EXPallo values were estimated
for clearance and volume of distribution parameters.
2.6 | PK parameter evaluation
Individual (posthoc) PK parameters were estimated by maximum a
posteriori Bayesian analysis using the final model with inclusion of the
morphometric variable. For each patient, terminal elimination half-life
and IVR were calculated. The IVR was obtained by dividing BW of
the patients by the individual PK parameter estimate for V1. A
Kruskall–Wallis test was used to compare the individual PK parameter
estimates obtained for the patients from the 3 BMI categories, as the
data were not normally distributed. P-values <.01 were considered
statistically significant.
2.7 | Simulations of single dose and dosing of FVIII
concentrate in case of a life-threatening bleed
For all patients in this cohort, peak and trough FVIII levels were
simulated after a single dose of 50 IU kg−1, and after treating a life-
threatening bleed by infusing a loading dose of 50 IU kg−1 followed
by a twice daily dose of 25 IU kg−1. The trough FVIII levels were
obtained immediately before the sixth dose, which corresponded with
TABLE 1 General characteristics of the study population
Total population
BMI BMI BMI
<25 kg m–2 25 kg m–2 ≤ and <30 kg m–2 ≥30 kg m–2
Patient characteristics
Total no. of patients 57 26 21 10
Age (y) 48.0 [18.4–76.9] 36.0 [18.4–69.1] 53.4 [26.9–76.9] 48.7 [32.3–70.9]
Severe haemophilia A (<0.01 IU mL−1) 37 (65) 18 (69) 12 (57) 7 (70)
Blood group O† 31 (54) 14 (54) 12 (57) 5 (50)
Height (m) 1.78 [1.48–1.95] 1.77 [1.58–1.95] 1.81 [1.48–1.95] 1.76 [1.68–1.92]
Body weight (kg) 83.0 [53.0–133] 73.0 [53.0–92.0] 88.5 [60.8–113] 99.6 [93.0–133]
Adjusted body weight (kg) 77.5 [51.9–104] 73.0 [54.2–89.9] 81.9 [51.9–98.5] 83.5 [76.7–104]
BMI (kg m–2) 26.3 [19.0–42.6] 23.3 [19.0–24.9] 27.9 [25.5–29.9] 32.4 [30.7–42.6]
Ideal body weight (kg) 73.1 [46.0–88.5] 72.2 [55.0–88.5] 75.9 [46.0–88.5] 71.3 [64.1–85.8]
Lean body mass measured (kg) 61.4 [39.4–83.5] 57.9 [39.4–76.5] 62.5 [40.6–80.8] 64.9 [57.7–83.5]
Lean body mass calculated (kg) 62.8 [43.6–85.2] 57.4 [43.6–71.6] 66.9 [44.4–80.1] 68.3 [63.2–85.2]
Type of clotting factor concentrate
Advate 34 (59.6) 15 (57.7) 13 (61.9) 6 (60.0)
Aafact 1 (1.8) 0 (0.0) 1 (4.8) 0 (0.0)
Kogenate FS 13 (22.8) 6 (23.1) 4 (19.0) 3 (30.0)
NovoEight 5 (8.8) 3 (11.5) 1 (4.8) 1 (10.0)
Refacto AF 4 (7.0) 2 (7.7) 2 (9.5) 0 0
Pharmacokinetic data
Total number of observations 173 80 63 30
No. of observations per individual 3 [2–4] 3 [3–4] 3 [2–4] 3 [3–3]
No. of prior doses per individual 3 [1–6] 3.5 [1–6] 2 [1–5] 4 [1–4]
No. of observations day 1 (>0–12 h) 63 (36) 30 (38) 23 (37) 10 (33)
No. of observations day 2 (>12– 36 h) 56 (32) 25 (31) 21 (33) 10 (33)
No. of observations day 3 (>36–72 h) 54 (31) 25 (31) 19 (30) 10 (33)
BMI = body mass index. † Blood group available in 56 patients. Data are n (%) or median [range]
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72 hours after administration of the loading-dose. A Kruskall–Wallis
test was used to compare the FVIII levels and P-values <.01 were
considered statistically significant.
Monte Carlo simulations were additionally performed to simulate
a total of 1000 haemophilia A patients, receiving dosages based on
BW and IBW for a life-threatening bleed at time point of 72 hours,
after 5 consecutive FVIII concentrate doses of 50 IU kg−1; 2 days of
25 IU kg−1 every 12 hours.
3 | RESULTS
3.1 | Patient characteristics
In total, 57 severe and moderate haemophilia A patients were
included with a median BW of 83 kg (range: 53–133 kg) and a median
age of 48 years (range: 18.4–76.9 years). In the 3 BMI categories,
26 patients (46%) had a normal BW, 21 patients (37%) were
overweight, and 10 patients (18%) were obese. General patient char-
acteristics of the study population and medians and ranges of the
morphometric variables are presented in Table 1. In this study, LBM
was not measured for 2 patients (4%), due to logistical reasons. In
these patients, median measured LBM of the population was used
instead.
3.2 | PK modelling
A 2-compartment model performed best as structural model
(Table 2). IIV could be estimated for both CL and V1. Inclusion of a
correlation between the IIV of both parameters allowed a signifi-
cantly better fit of the model with measured FVIII levels. In
Figure S2, the goodness-of-fit of the structural model is presented.
Although a small deviation of population predictions of highest FVIII
levels was observed, the main part of population predictions was
TABLE 2 Estimated population pharmacokinetic parameters for structural model and final model
Structural model Final model
Estimate RSE (%) Shr. [%] Estimate RSE (%) Shr. [%]
Structural model
Clearance (CL; mL h−1) 242 (6) 236 (5)
Volume of central compartment (V1; mL) 2620 (19) 2840 (8)
Distribution CL to compartment 2 (Q; mL h−1) 192 (62) 122 (24)
Volume of compartment 2 (V2; mL) 1070 (37) 821 (47)
IIV
IIV on CL (%) 45.1 (20) [1] 37.6 (19) [2]
IIV on V1 (%) 26.8 (62) [20] 14.1 (95) [37]
Correlation between CL and V1 66.4 (46) 45.6 (64)
Residual variability
Additive residual variability (IU dL−1) 0.66 (47.1) 0.65 (35)
Proportional residual variability (%) 13.8 (23) 13.7 (22)
Covariate relations
CL: allometric exponent - 1.65 (21)
V1: allometric exponent - 1.34 (19)
Model characteristics
Objective function value −186.1 −217
Condition number 332 99
RSE: relative standard error. Shr.: shrinkage. IIV: interindividual variability. The individual values for the clearance parameters (CL, Q) and the volume of
distribution parameters (V1, V2) from the final model are described by the following equations:
CLi = 236x IBWIBWmed
 1:65
x eηCL,i
V1i = 2840x IBWIBWmed
 1:34
x eηV1,i
Qi = 122x IBWIBWmed
 1:65
V2i = 821x IBWIBWmed
 1:34
in which IBW is the value for the ideal body weight and IBWmed is the median of for the ideal body weight from the studied population.
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distributed symmetrically around the line y = x demonstrating
adequacy of the model to describe measured FVIII levels. When
accounting for IIV by Bayesian analysis, the individual profiles were
also well described, as practically all predictions were present on
the line y = x (Figure S1-B). Furthermore, the visual predictive check
(VPC) showed a good description of the data, and that the model
was able to accurately predict the FVIII levels of each patient
(Figure S3).
3.3 | Evaluation of the morphometric variables
The established structural model was used to evaluate the ability of
morphometric variables to explain the IIV of CL and V1. In Table 3, a
summary of all allometric scaling evaluations with the 5 morphometric
variables is presented. Looking at the models in which the allometric
exponents were fixed, scaling parameters with IBW produced the
lowest AIC and the greatest reduction of IIV from V1. Interestingly,
TABLE 3 Summary of the covariate relationship selection process
Model and parameter Covariate OFV AIC dAIC IIV on CL IIV on V1 Correlation between CL & V1
Comparator model −186.1 −168.1 45.1 26.8 66.4
Allometric scaling with fixed exponents
WT −176.2 −158.2 9.9 43.7 26.7 60.1
LBM −208.1 −190.1 −22.1 39.5 16.4 46.7
IBW −212.1 −194.1 −26.0 40.2 15.6 52.9
BMI −160.9 −142.9 25.2 47.7 34.1 69.3
ABW −200.7 −182.7 −14.6 41.2 18.9 55.7
LBMc −197.3 −179.3 −11.3 42.1 20.4 58.1
Allometric exponents estimated for CL & V1
WT −190.6 −168.6 −0.5 43.9 23.8 64.2
LBM −212.6 −190.6 −22.5 37.3 15.7 46.2
IBW −217.2 −195.2 −27.2 37.6 14.1 45.6
BMI −186.8 −164.8 3.3 44.8 26.7 66.1
ABW −202.3 −180.3 −12.2 40.7 18.7 57.0
LBMc −198.8 −176.8 −8.7 41.9 20.2 60.1
OFV: objective function value; AIC: Akaike information criterion; dAIC: change in the AIC as compared to the AIC from the comparator model; IIV:
interindividual variability; CL: clearance of the central compartment; V1: volume of distribution of the central compartment; WT: body weight; LBM:
measured lean body mass; IBW: ideal body weight; BMI: body mass index; ABW: adjusted body weight; LBMc: calculated lean body mass.
F IGURE 1 Clearance and volume of distribution increase when ideal body weight increases. (A) Clearance. (B) Volume of distribution of the
central compartment. The individual PK parameter estimates were obtained by posthoc analysis using the final model. The blue line depicts the
typical values, as calculated using the final model vs ideal body weight. In both figures, an increase is demonstrated for the typical value with
increasing ideal body weight
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allometric scaling using the BW of the patient resulted in a worse fit
as compared with the model without allometric scaling, which signifies
the need for allometric scaling using an adequate predictor.
IBW best explained the interpatient variability in FVIII PK. Scaling
PK parameters by IBW reduced the interpatient variability in CL and
V1 from 45.1 to 37.6% and from 26.8 to 14.1%, respectively. However,
the obtained IIV on CL using allometric scaling with LBM (37.3%) was
similar to the IIV obtained using allometric scaling with IBW (37.6%),
whereas not for the IIV obtained for V1 (15.7%). Nevertheless, a signif-
icant difference was obtained in the ability of the model to describe
the measured FVIII data favouring allometric scaling using IBW.
3.4 | PK parameter evaluation
In the final population model with parameters scaled for IBW,
the allometric exponents for CL and V1 were estimated (Table 2). As
both estimated allometric exponents were above 1, the relation with
IBW allowed a more than proportional increase for the individual PK
parameters CL and V1. The relationship between IBW and the individ-
ual PK parameter estimates is shown in Figure 1. However, the
η-shrinkage of the IIV on V1 is quite large (37%). Nevertheless, the
conclusion still stands that with increasing IBW, the typical (median)
values for CL and V1 also increase.
In Figure 2, the individual posthoc PK parameter estimates for
FVIII CL, V1, terminal half-life and the calculated IVR are pres-
ented. For CL, V1 and terminal half-life, no significant differences
were obtained for the values obtained within the 3 BMI categories.
This shows that CL, V1 and terminal half-life were similar between
normal weight, overweight and obese haemophilia A patients.
However, the calculated IVR increased with increasing BMI and
the values from the 3 BMI categories were significantly different
(χ2 = 28.8, P < .001).
F IGURE 2 No differences in individual pharmacokinetic (PK) parameters (clearance, volume of distribution and terminal half-life) between
BMI categories. (A) Clearance. (B) volume of distribution of the central compartment. (C) Terminal elimination half-life. (D) Calculated in vivo
recovery. The in vivo recovery was calculated using the body weight of the patient divided by the individual PK parameters estimates for V1. For
each boxplot, the whiskers depict the 2.5th and 97.5th percentile of the data, whereas the box depicts the interquartile range. The median of the
data is depicted by the black horizontal line inside the boxplot
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3.5 | Dosing in case of life-threatening bleed
PK simulations were performed using posthoc PK parameters from
each patient included in this study. BW and IBW were used to calcu-
late the dose required in 2 clinical situations: a single dose of
50 IU kg−1, which may be a test dose for PK profiling, and a dose
required to treat a life-threatening bleed with a loading dose of
50 IU kg−1 followed by a twice daily dose of 25 IU kg−1. In Figure 3,
simulations are presented for 1 typical normal weight, 1 typical
overweight and 1 typical obese patient. For the patient with a
BMI <25 kg m−2, no difference was observed between the FVIII levels
calculated using BW or IBW. For the 2 other BMI categories, differ-
ences increased with increasing BMI for both achieved FVIII peak and
trough levels. Importantly, dosing based on IBW resulted in similar
peak and trough levels for each BMI category.
Figure 4 depicts the simulated FVIII trough and peak levels for all
patients included in this cohort when treating a life-threatening bleed
by a loading dose of 50 IU kg−1 followed by doses of 25 IU kg−1 twice
daily. In all patients with dosing based on IBW, no statistical
differences were obtained for both FVIII peak (χ2 = 1.1, P = .57) and
trough (χ2 = 2, P = .37) levels, whereas dosing based on BW resulted
in significant differences for both FVIII peak (χ2 = 33.5, P < .001) and
trough (χ2 = 9.43, P < .009) levels. This demonstrates that dosing
based on BW results in unnecessary high peak levels in overweight/
obese patients.
Figure 5 shows additional Monte Carlo simulations for a total
of 1000 simulated patients to assess potential risks involved with
the proposed model. Simulations show that dosing based on IBW
for a life-threatening bleed results in median trough levels of 0.40,
0.46 and 0.40 IU mL−1 for normal BMI, overweight and obese
patients, respectively when dosed according to national guidelines.
In contrast, dosing based on BW compensated the lower FVIII
trough levels in the overweight and obese patients, although strik-
ingly under dosing still occurred in patients with normal BMI when
dosed according to BW. For the FVIII peak levels, dosing based on
IBW prevent high FVIII peaks, while dosing based on BW resulted
in unnecessary high peaks (supplementary table 3). In conclusion,
dosing based on IBW prevents high FVIII peak levels, but is not
superior when taking into account FVIII trough levels to treat life-
threatening bleeds. Critical analysis of current dosing strategies
shows that dosing based on BW may lead to under dosing in cases
of life-threatening bleeds.
F IGURE 3 Coagulation factor VIII (FVIII) dosing based on body weight and ideal body weight in a normal weight, overweight and obese
patient. The 3 examples were obtained by selecting typical patients from each body mass index (BMI) category; normal weight (BMI <25 kg m−2),
overweight (BMI 25–30 kg m−2) and obese (BMI >30 kg m−2) patient. The lines from the plot depict the individual predicted FVIII levels after a
simulated single-dose of 50 IU kg−1 (upper panels). In the lower panels, a simulated loading-dose was administered of 50 IU kg−1 followed by
twice daily dosing of 25 IU kg−1 to treat a life-threatening bleed. The individual FVIII levels were estimated using the individual pharmacokinetic
(PK) parameters from the corresponding example patients
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4 | DISCUSSION
In this study, the relationship between 5 morphometric variables
(e.g. IBW, BMI, LBM, adjusted BW and calculated LBM) and the PK of
FVIII concentrates was investigated in normal weight, overweight and
obese haemophilia A patients. IBW best explained the interpatient
variability in FVIII PK. Scaling PK parameters by IBW reduced the
interpatient variability in CL and V1 from 45.1 to 37.6% and from
26.8 to 14.1%, respectively. CL, V1 and FVIII half-life were similar
between normal, overweight and obese patients while IVR increased
with increasing BMI. This was also demonstrated in additional simula-
tions of included study patients, in which it was observed that FVIII
peak levels increased to unnecessary high values when dosing was
based on BW in the overweight/obese patients. Dosing based on
IBW was shown to prevent excessively high FVIII peak levels, but was
not able to maintain FVIII trough levels >0.50 IU mL−1, when dosing
according to national guidelines of The Netherlands.
Allometric scaling can be applied to partly explain IIV for a popu-
lation PK parameter. By inclusion of allometric scaling, the fit of the
model to collected data may improve, resulting in more accurate
estimation of individual PK parameters required to calculate individu-
alized doses. Although BW is generally used for allometric scaling,
other morphometric variables can also be applied. Therefore, which
morphometric variable correlated best with FVIII PK parameters was
investigated. It was demonstrated that a more adequate fit was
obtained using allometric scaling with IBW, reducing IIV of CL by
7.5% and V1 by 12.7%. If BW was used, IIV of CL and V1 was only
reduced with 1.2 and 3%, respectively. Therefore, we conclude that
IBW should be used for allometric scaling instead of BW in over-
weight and obese haemophilia A patients.
No differences were found in the estimated individual PK param-
eters (CL, V1 and half-life) between normal weight, overweight and
obese patients. Previous studies have demonstrated that increasing
BMI results in higher von Willebrand factor (VWF) levels in both
healthy individuals and haemophilia A patients.21–23 This may be cau-
sed by increased shear stress upon the vessel wall caused by hyper-
tension and atherosclerosis and subsequent secretion of VWF.24
Furthermore, it has been shown that adipose tissue expresses VWF.25
As VWF protects FVIII from proteolytic cleavage, it could be expected
that FVIII CL may decrease with increasing BMI. However, the
F IGURE 4 Dosing based on ideal body weight results in adequate coagulation factor VIII (FVIII) peak and trough levels when treating a life-
threatening bleed. The FVIII peak levels (upper panels) were obtained 5 minutes after the simulated loading-dose of 50 IU kg−1, which was
followed by twice daily dosing of 25 IU kg−1 to treat a life-threatening bleed. The trough FVIII levels (lower panels) were obtained immediately
before the sixth dose, which corresponded with 72 hours after administration of the loading-dose. The individual FVIII levels were simulated
using the individual pharmacokinetic (PK) parameters from each included real-life patient of the studied population. The blue bar depicts the
median FVIII level. To enhance the visibility for the number of FVIII levels in each category, the FVIII levels were scattered horizontally
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estimated individual PK parameters showed no differences in FVIII
CL, V1 and FVIII half-life between normal weight, overweight and
obese haemophilia A patients.
Applying maximum a posteriori Bayesian analysis using the
established population PK model to calculate FVIII doses is only possi-
ble when the source data are generalizable to the population which
you wish to dose. Due to rising prevalence of obesity, overweight and
obese patients should be adequately represented in the population
used to construct population PK models. This fact also emphasizes
that other morphometric variables instead of BW may be more
adequate to calculate doses. The applied population PK model in this
study was able to adequately fit FVIII levels obtained in all patients, as
in the study population 36.8% of the patients were overweight and
17.5% were obese. Moreover, the population PK model was able to
adequately fit FVIII levels obtained in all patients. Therefore, the
established population PK model can be applied to the current
haemophilia A patient population.
Simulations of the included real-life patients on the basis of this
population PK model using real-world data, showed that dosing based
on IBW resulted in adequate FVIII peak to treat or prevent a life-
threatening bleed, a circumstance during which it is required to
achieve FVIII peak of 0.80–1.0 IU mL−1. However, the recommended
dosing schedule of a loading dose of 50 IU kg−1 followed by
25 IU kg−1 twice a day does not result in adequate trough levels, both
in case of dosing based on BW and IBW. This suggests that higher
dosages may be needed to maintain adequate trough levels. These
dosages should be based on IBW to prevent unnecessary high FVIII
peak levels. When dosing FVIII based on IBW, interindividual differ-
ences in FVIII PK however do still exist. The variation in FVIII peak
and trough levels in obese patients were comparable to levels
obtained for the nonobese patients. It is always important to realize
that IIV in bleeding tendency e.g. bleeding phenotype is notably
large and not always explained by the FVIII levels measured after FVIII
concentrate infusion. Nevertheless, clinical guidelines advise specific
FVIII levels to prevent or treat bleeding in certain settings, and in clini-
cal practice these dosing strategies reduce this variability in response.
It must also be realized and anticipated that clearance and volume of
distribution may alter in a situation of a life-threatening bleeding risk,
which we have not been able to simulate in this study.
The potential use of alternative morphometric variables for allo-
metric scaling of model parameters has been addressed in previous
studies. Garmann et al. constructed a population PK model for
F IGURE 5 Monte Carlo simulations show adequate coagulation factor VIII (FVIII) levels when dosing is based on ideal body weight.
Simulations were performed (n = 1000) using Monte Carlo simulations. The green bold line depicts the median FVIII level when dosing is based on
ideal bodyweight and the green shade represents the corresponding 95% confidence interval. The bold red line represents the median FVIII level
when dosing is based on actual bodyweight, whereas the red shades represent the 95% confidence interval. Both the upper and lower left panel
do not show red lines (dosing based on bodyweight) or shades as they completely overlap with the green lines (dosing based on ideal
bodyweight). The lines from the upper plots depict the predicted FVIII levels after a simulated single-dose of 50 IU kg−1. In the lower panels, a
simulated loading-dose was administered of 50 IU kg−1 followed by twice daily dosing of 25 IU kg−1 to treat a life-threatening bleed
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recombinant FVIII (rFVIII) concentrate, in which scaling was investi-
gated using only BW and LBM.26 This model was based on informa-
tion from both children and adults with a median age of 22 years
(range: 1–61 year). It is known that LBM should preferably be
corrected when used in children.27 However, the authors did not
report whether they used different formulas to calculate LBM, while
they did include LBM for allometric scaling of parameters in their final
model.26 In McEneny-King et al., this model was subsequently applied
to perform a simulation study, in which alternative dosing strategies
of 1 brand of rFVIII concentrate based on various morphometric vari-
ables were simulated in 1000 normal weight (BMI <29.6 kg m−2) and
1000 overweight/obese (BMI 29.6–40.0 kg m−2) patients.13 Although
a different cut-off point (BMI: 29.6 kg m−2) was applied to discrimi-
nate between normal and overweight/obese patients than used in the
present study, it was also concluded that IBW demonstrates best pre-
dictive performance across all of the investigated dosing regimens.
The present study using real-world and simulated data, substantiates
the conclusion that IBW is the best morphometric variable to explain
the variability in PK in haemophilia A patients with varying FVIII
concentrates.
In conclusion, this study investigated the relationship between
5 morphometric variables and FVIII PK in normal weight, overweight
and obese haemophilia A patients. Scaling of the model parameters
using IBW best explained the IIV of PK parameters and provided the
most optimal description of the measured FVIII levels. Additional
research is needed to specifically develop adequate dosing schedules
based on IBW to treat life-threatening bleeds. If future dosing strate-
gies are indeed based on IBW to prevent excessive dosing in daily
practice, higher dosing may be needed to adequately treat bleeding in
critical circumstances.
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